[ORGANIZATION]
Novo Nordisk
Featured in 1 tracked story · first seen
Situations
Novo Nordisk obesity portfolio: EU approval, legal fight
93 clusters · 431 sources · last updated
Latest: US Medicare Launches GLP-1 Bridge Program to Cut Drug Costs
Novo Nordisk’s obesity portfolio keeps expanding. The European Commission confirmed marketing authorisation for the once‑daily 25 mg oral semaglutide (Wegovy) tablet, the first oral GLP‑1 approved for weight management i